Bąk et al. identified three patients with AML with germline RUNX1 variants in a cohort of 100 patients [17], and Ernst et al. showed that 8% of patients with AML who achieved complete remission had a persistent RUNX1 variant throughout baseline and after achieving complete remission [18]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.